(Refiles to fix typo in country name)
NAIROBI/DAKAR, June 16 (Reuters) – Lead vaccine candidates developed by Oxford University and Moderna against Ebola Bundibugyo, the deadly virus that has swept through eastern Democratic Republic of Congo, could enter Phase 1 trials as early as July, with field trials possible within several months, the head of the Coalition for Epidemic Preparedness Innovations, Richard Hatchett, said on Tuesday.
(Reporting by Anait Miridzhanian and Emma Farge; Editing by Alison Williams)
